4-Amino-3-Chlorophenol Hydrochloridis CAS 52671-64-4 Lenvatinib Mesylate puritate media >98.0% (HPLC)
Ruifu Chemical Supple Lenvatinib Mesylate media cum puritate
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl) -3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylatus CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylatus CAS 205448-66-4
Nomen chemicum | 4-Amino-3-Chlorophenolum Hydrochloridum |
Synonyma | 2-Chloro-4-Hydroxyaninum Hydrochloridum |
CAS Number | 618-89-3 |
CATTUS Number | RF-PI1969 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C6H6ClNO·HCl |
M. Pondus | 180.03 |
Liquescens punctum | 254.0~ 256.0'(decl.)(lit.) |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Firmus Pulvis Brown |
Puritas / Analysis Methodus | >98.0% (HPLC) |
Puritas / Analysis Methodus | 97.5~ 102.5% (Titration by AgNO3) |
Damnum in Siccatio | <0.50% |
Residere in Ignition | <0.30% |
Totalis immunditias | <2.00% |
Infrared Imaginis | Conformat ut Structure |
Proton NMR Spectrum | Conformat ut Structure |
Test Standard | Enterprise Standard |
Consuetudinem | Medium de Mesylate Lenvatinib (CAS: 857890-39-2) |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore
4-Amino-3-chlorophenolum hydrochloridum (CAS: 52671-64-4) medium est Mesylate Lenvatinib (CAS: 857890-39-2).Lenvatinib (nomen Lenvima artis) medicamentum anti-cancri est pro curatione quarundam generis cancri thyroideae, et in potentia ad alias carcinomata.Lenvatinib adhibetur pro curatione cancri thyroideae differentiatae, quae vel localiter recurrens ormetastaticum, progressivum est, nec curationi cum iodi radioactivo (radioiodine) respondet. LENVATINIB medicina est quae scuta in cellis cancri sistit et cellas cancer accrescens sistit.Adhibetur ut cancer thyroideum et renum cancrum tractare.Compare kinase inhibitores.Lenvatinib inhibitor scuti multi-VEGFR2 et VEGFR3 cum IC50 4 nM et 5.2 nM, respective.